KR20130110170A - 치환된 뉴클레오타이드 유사체 - Google Patents

치환된 뉴클레오타이드 유사체 Download PDF

Info

Publication number
KR20130110170A
KR20130110170A KR1020137010099A KR20137010099A KR20130110170A KR 20130110170 A KR20130110170 A KR 20130110170A KR 1020137010099 A KR1020137010099 A KR 1020137010099A KR 20137010099 A KR20137010099 A KR 20137010099A KR 20130110170 A KR20130110170 A KR 20130110170A
Authority
KR
South Korea
Prior art keywords
compound
optionally substituted
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137010099A
Other languages
English (en)
Korean (ko)
Inventor
데이빗 버나드 스미스
제롬 드발
나탈리아 드얏키나
레오니드 베이겔만
광위 왕
Original Assignee
앨리오스 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45818284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130110170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 앨리오스 바이오파마 인크. filed Critical 앨리오스 바이오파마 인크.
Publication of KR20130110170A publication Critical patent/KR20130110170A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137010099A 2010-09-22 2011-09-19 치환된 뉴클레오타이드 유사체 Ceased KR20130110170A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38536310P 2010-09-22 2010-09-22
US61/385,363 2010-09-22
US201061426461P 2010-12-22 2010-12-22
US61/426,461 2010-12-22
PCT/US2011/052220 WO2012040127A1 (en) 2010-09-22 2011-09-19 Substituted nucleotide analogs

Publications (1)

Publication Number Publication Date
KR20130110170A true KR20130110170A (ko) 2013-10-08

Family

ID=45818284

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137010099A Ceased KR20130110170A (ko) 2010-09-22 2011-09-19 치환된 뉴클레오타이드 유사체

Country Status (24)

Country Link
US (2) US8871737B2 (https=)
EP (1) EP2619216A4 (https=)
JP (2) JP6012605B2 (https=)
KR (1) KR20130110170A (https=)
CN (2) CN105061534A (https=)
AP (1) AP3584A (https=)
AR (1) AR083070A1 (https=)
AU (1) AU2011305655B2 (https=)
BR (1) BR112013005872A2 (https=)
CA (1) CA2810928A1 (https=)
CL (1) CL2013000755A1 (https=)
CO (1) CO6690792A2 (https=)
EA (1) EA025341B1 (https=)
EC (1) ECSP13012572A (https=)
GE (1) GEP20156313B (https=)
HK (1) HK1216254A1 (https=)
MX (1) MX2013003153A (https=)
NZ (1) NZ607996A (https=)
PE (2) PE20171640A1 (https=)
PH (2) PH12013500629A1 (https=)
SG (1) SG188497A1 (https=)
TW (1) TW201217392A (https=)
UY (1) UY33621A (https=)
WO (1) WO2012040127A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230028486A (ko) * 2020-06-24 2023-02-28 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오시드 유사체 및 이의 용도

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521359A (ja) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
MX2012003126A (es) 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
CA2819041A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
DK3031812T3 (en) 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
CA2836579A1 (en) * 2011-05-19 2012-11-22 Rfs Pharma, Llc Purine monophosphate prodrugs for treatment of viral infections
US9408863B2 (en) * 2011-07-13 2016-08-09 Merck Sharp & Dohme Corp. 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
MX350810B (es) 2011-12-20 2017-09-20 Riboscience Llc Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) * 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US8846896B2 (en) * 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
HK1206362A1 (zh) * 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
GEP201706721B (en) * 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142157A1 (en) * 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
ES2671478T3 (es) 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
WO2014047117A1 (en) * 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10034893B2 (en) * 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014137930A1 (en) * 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
AU2014225052B2 (en) * 2013-03-08 2016-11-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Novel nucleoside phosphoramidate compound and use thereof
WO2014164533A1 (en) * 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
CA2908313A1 (en) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Hepatitis c viral infection treatment using a combination of compounds
US9447132B2 (en) 2013-04-12 2016-09-20 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
JP6366693B2 (ja) * 2013-05-16 2018-08-01 リボサイエンス・エルエルシー ４’−フルオロ−２’−メチル置換ヌクレオシド誘導体
MA38678A1 (fr) 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
US10005779B2 (en) * 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2014194826A1 (zh) * 2013-06-06 2014-12-11 南京圣和药业有限公司 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2015017556A (es) 2013-06-26 2016-05-09 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
CN103288906A (zh) * 2013-06-26 2013-09-11 湖南欧亚生物有限公司 3,5-双-o-苯甲酰基-2-c-甲基c-甲基-4-(1,2,4-三唑基)尿苷及其合成方法
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015054465A1 (en) * 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20160271162A1 (en) * 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) * 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
HUE051986T2 (hu) * 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
EP3160978B1 (en) 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
CN104130302B (zh) * 2014-08-08 2017-02-15 乳源东阳光药业有限公司 一种核苷药物的晶型及其制备方法
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016044243A1 (en) * 2014-09-16 2016-03-24 Achillion Pharmaceuticals, Inc. Pyrimidine nucleoside phosphoramidate
WO2016069489A1 (en) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
TWI678373B (zh) * 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
LT3224268T (lt) * 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN107428792B (zh) 2014-12-15 2023-01-24 埃默里大学 用于治疗乙型肝炎病毒的磷酰胺
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US20160237106A1 (en) * 2015-01-14 2016-08-18 Riboscience Llc 4'-azido substituted nucleoside derivatives as inhibitors of ebola virus rna replication
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
CA2984421C (en) * 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
DK3785717T3 (da) 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
KR20190057277A (ko) 2016-06-24 2019-05-28 에모리 유니버시티 B형 간염 바이러스 치료용 포스포아미데이트
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
TW201811339A (zh) 2016-08-12 2018-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CA3075950A1 (en) * 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
CN109575022B (zh) * 2017-12-25 2021-09-21 成都海博锐药业有限公司 一种化合物及其用途
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US20230405003A1 (en) * 2020-10-30 2023-12-21 Onquality Pharmaceuticals China Ltd. Application of thymidine derivative in preparation of drugs
WO2022174194A1 (en) * 2021-02-15 2022-08-18 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2022174779A1 (zh) * 2021-02-19 2022-08-25 南京赛弗斯医药科技有限公司 一种具有抗肿瘤活性的核苷酸衍生物及其药物组合物和用途
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN116411028B (zh) * 2023-01-06 2024-08-16 西南大学 桔小实蝇嗅觉受体OR43a-1和OR63a-2的应用及其突变体的构建方法

Family Cites Families (362)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844579A (en) 1958-07-22 Process for thiamine monomtrate
US3180859A (en) 1962-12-05 1965-04-27 Upjohn Co Derivatives of decoyinine and process for preparing same
US3431252A (en) 1966-04-01 1969-03-04 Merck & Co Inc 5,5-dialkyl-d-ribofuranosyl purine compounds and intermediates
US3480613A (en) 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
GB1319303A (en) 1970-07-14 1973-06-06 Univ Bradford Sugar derivatives
US3816399A (en) 1970-07-14 1974-06-11 Univ Bradford 1-amine nucleosides
US3872098A (en) 1972-10-10 1975-03-18 Syntex Inc 1,n{hu 6{b ethenoadenosine cyclophosphate compounds
US3872084A (en) 1972-10-10 1975-03-18 Syntex Inc Purine nucleoside 3,5-cyclicphosphate compounds
US4093714A (en) 1974-03-15 1978-06-06 Icn Pharmaceuticals, Inc. 9β-D-Arabinofuranosylpurine nucleotides and method of use
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
PL144471B1 (en) 1985-04-22 1988-05-31 Polska Akad Nauk Centrum Method of obtaining novel 3',5'-cyclic adensine dithiophosphate
ES8801303A1 (es) 1985-05-15 1987-12-16 Wellcome Found Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
WO1988003147A1 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
IL86007A0 (en) 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
DE8708526U1 (de) 1987-06-19 1987-08-27 REHAU AG + Co, 8673 Rehau Möbelfuß
US4885739A (en) 1987-11-13 1989-12-05 Dsc Communications Corporation Interprocessor switching network
DE3824110A1 (de) 1988-07-15 1990-01-18 Max Planck Gesellschaft Verfahren zur herstellung und reinigung von an ihrem 5'-ende phosphorylierten oligo- und jpolynukleotidsequenzen und reagenz zur durchfuehrung des verfahrens
AU4479189A (en) 1988-11-21 1990-06-21 Syntex (U.S.A.) Inc. Antiviral agents
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US6087482A (en) 1990-07-27 2000-07-11 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO1992012718A1 (en) 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
HUT67392A (en) 1991-05-15 1995-04-28 Univ Yale Determination of prodrugs metabolizable by the liver and therapeutic use thereof
IT1249732B (it) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso.
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5714383A (en) 1992-05-14 1998-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treating chronic myelogenous leukemia
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5686599A (en) 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5625056A (en) 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
WO1993025566A1 (en) 1992-06-18 1993-12-23 Jyoti Chattopadhyaya Deuterated nucleosides
US5837542A (en) 1992-12-07 1998-11-17 Ribozyme Pharmaceuticals, Inc. Intercellular adhesion molecule-1 (ICAM-1) ribozymes
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
US5811300A (en) 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5616488A (en) 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
JPH06228186A (ja) 1993-01-29 1994-08-16 Yamasa Shoyu Co Ltd ２’−デオキシ−（２’ｓ）−アルキルピリミジンヌクレオシド誘導体
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
WO1994022890A1 (en) 1993-03-31 1994-10-13 Sterling Winthop Inc. Novel 5'-substituted nucleosides and oligomers produced therefrom
HU9501978D0 (en) 1993-03-31 1995-09-28 Sterling Winthorp Inc Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
GB9311682D0 (en) 1993-06-05 1993-07-21 Ciba Geigy Ag Chemical compounds
US6491905B1 (en) 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
US6017896A (en) 1993-09-14 2000-01-25 University Of Alabama Research Foundation And Southern Research Institute Purine nucleoside phosphorylase gene therapy for human malignancy
US5552311A (en) 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
ATE174600T1 (de) 1993-10-27 1999-01-15 Ribozyme Pharm Inc 2'-amido-und 2'-peptido-modifizierte oligonukleotide
DE4341161A1 (de) * 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
AU1436995A (en) 1993-12-30 1995-07-17 Chemgenes Corporation Synthesis of propargyl modified nucleosides and phosphoramidites and their incorporation into defined sequence oligonucleotides
US5693532A (en) 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5639647A (en) 1994-03-29 1997-06-17 Ribozyme Pharmaceuticals, Inc. 2'-deoxy-2'alkylnucleotide containing nucleic acid
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US6639061B1 (en) 1999-07-07 2003-10-28 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate oligomers and related compounds
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5580967A (en) 1994-05-13 1996-12-03 The Scripps Research Institute Optimized catalytic DNA-cleaving ribozymes
US6063566A (en) 1994-05-13 2000-05-16 The Scripps Research Institute Catalytic RNA molecules
GB9417746D0 (en) 1994-09-03 1994-10-19 Ciba Geigy Ag Chemical compounds
GB9417938D0 (en) 1994-09-06 1994-10-26 Ciba Geigy Ag Compounds
US5681940A (en) 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US7141665B1 (en) 1998-04-29 2006-11-28 The Scripps Research Institute Enzymatic DNA molecules
WO1996023506A1 (de) 1995-02-01 1996-08-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
WO1996030383A1 (de) 1995-03-24 1996-10-03 Christian Noe Nukleinsäure-polyester-polyamide
US5968745A (en) 1995-06-27 1999-10-19 The University Of North Carolina At Chapel Hill Polymer-electrodes for detecting nucleic acid hybridization and method of use thereof
US6361951B1 (en) 1995-06-27 2002-03-26 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US6132971A (en) 1995-06-27 2000-10-17 The University Of North Carolina At Chapel Hill Microelectronic device
US6004939A (en) * 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
US20010011075A1 (en) 1999-02-05 2001-08-02 Leroy B Townsend 5'-substituted-ribofuranosyl benzimidazoles as antiviral agents
WO2002096927A2 (en) 2001-05-29 2002-12-05 Ribozyme Pharmaceuticals, Incorporated Ribozyme based treatment of female reproductive diseases
WO1997026270A2 (en) 1996-01-16 1997-07-24 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
EP0799834A1 (en) 1996-04-04 1997-10-08 Novartis AG Modified nucleotides
US20050032067A1 (en) 2002-11-05 2005-02-10 Prakash Thazha P. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US20040171032A1 (en) 1996-06-06 2004-09-02 Baker Brenda F. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US20050042647A1 (en) 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US20040171028A1 (en) 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
WO1998000434A1 (en) 1996-06-28 1998-01-08 Novartis Ag Modified oligonucleotides
NZ505531A (en) 1996-10-16 2001-08-31 Icn Pharmaceuticals 7-Propyl-8-oxo-alpha or beta-L-guanine alpha or beta-L-nucleoside
ATE238328T1 (de) 1996-10-16 2003-05-15 Ribapharm Inc Monozyklische l-nukleoside, analoga und ihre anwendungen
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
NZ507848A (en) 1996-10-28 2005-01-28 Univ Washington Method of increasing the mutation rate of a virus in a non-human by administering an RNA nucleoside analogue to a virally infected cell
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US20030144489A1 (en) 1997-06-09 2003-07-31 Alex Burgin Method for screening nucleic acid catalysts
WO1999010365A2 (en) 1997-08-29 1999-03-04 Gilead Sciences, Inc. 5',5'-linked oligomers having anti-thrombin activity
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US6482932B1 (en) 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US20030004122A1 (en) 1997-11-05 2003-01-02 Leonid Beigelman Nucleotide triphosphates and their incorporation into oligonucleotides
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6015703A (en) 1998-03-10 2000-01-18 Iogen Corporation Genetic constructs and genetically modified microbes for enhanced production of beta-glucosidase
CA2330574A1 (en) 1998-04-29 1999-11-04 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into ribozymes
US6030957A (en) 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
US7091315B1 (en) 1998-07-15 2006-08-15 Human Genome Sciences, Inc. Protein HDPBQ71
WO2000014263A2 (en) 1998-09-03 2000-03-16 Board Of Regents, The University Of Texas System Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them
US6458945B1 (en) 1998-10-01 2002-10-01 Variagenics, Inc. Method for analyzing polynucleotides
US6566059B1 (en) 1998-10-01 2003-05-20 Variagenics, Inc. Method for analyzing polynucleotides
US6440705B1 (en) 1998-10-01 2002-08-27 Vincent P. Stanton, Jr. Method for analyzing polynucleotides
CA2252144A1 (en) 1998-10-16 2000-04-16 University Of Alberta Dual action anticancer prodrugs
US7064114B2 (en) 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
AU3903800A (en) 1999-03-19 2000-10-09 Parker Hughes Institute Gel-microemulsion formulations
US20040023265A1 (en) 1999-07-02 2004-02-05 Jeevalatha Vivekananda Methods and compositions for nucleic acid ligands against Shiga toxin and/or Shiga-like toxin
US6569630B1 (en) 1999-07-02 2003-05-27 Conceptual Mindworks, Inc. Methods and compositions for aptamers against anthrax
WO2001009318A1 (fr) 1999-07-29 2001-02-08 Helix Research Institute Genes associes au cancer du foie
AU769578B2 (en) 1999-08-27 2004-01-29 Icn Pharmaceuticals, Inc. Pyrrolo(2,3-d)pyrimidine nucleoside analogs
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US6649750B1 (en) 2000-01-05 2003-11-18 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotide compounds
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
KR20030005197A (ko) 2000-02-18 2003-01-17 샤이어 바이오켐 인코포레이티드 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
US7235649B2 (en) 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
CA2429196A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
FR2808797A1 (fr) 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives de l'uridine, leur procede de preparation et leur application comme medicaments
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
EA005890B1 (ru) 2000-05-26 2005-06-30 Айденикс (Кайман) Лимитед СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
WO2001092581A2 (en) 2000-05-26 2001-12-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
US20030207271A1 (en) 2000-06-30 2003-11-06 Holwitt Eric A. Methods and compositions for biological sensors
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US20030166064A1 (en) 2000-08-03 2003-09-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1346040A2 (en) 2000-09-11 2003-09-24 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2001296301A8 (en) 2000-09-26 2009-07-30 Human Genome Sciences Inc Nucleic acids, proteins, and antibodies
CN1133642C (zh) 2000-10-09 2004-01-07 清华大学 核苷5’-硫代磷酰氨基酸酯化合物
EP2180064A3 (en) 2000-10-18 2010-08-11 Pharmasset, Inc. Multiplex quantification of nucleic acids in diseased cells
WO2002058534A2 (en) 2000-11-20 2002-08-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
EP1364058A2 (en) * 2000-12-08 2003-11-26 Riken Method for maldi-tof-ms analysis and/or sequencing of oligonucleotides
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2002060317A2 (en) 2001-01-30 2002-08-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002069903A2 (en) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
EP1379264A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
AU2002338265A1 (en) 2001-03-28 2002-10-15 Incyte Genomics, Inc. Molecules for disease detection and treatment
US6995148B2 (en) 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
CN1186456C (zh) 2001-04-30 2005-01-26 曹卫 通用模板核酸检测方法和试剂盒
WO2002092006A2 (en) 2001-05-16 2002-11-21 Micrologix Biotech, Inc. Nucleic acid-based compounds and methods of use thereof
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
WO2003016572A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Oligonucleotide therapeutics for treating hepatitis c virus infections
AU2002329784A1 (en) 2001-08-17 2003-03-03 Incyte Genomics, Inc. Molecules for disease detection and treatment
CN1133641C (zh) 2001-08-24 2004-01-07 清华大学 一种含有3'叠氮胸苷的硫代磷酰氨基酸酯化合物及其制备方法
CN1159332C (zh) 2001-08-24 2004-07-28 清华大学 一种硫代磷酰氨基酸酯化合物及其制备方法
CN1186457C (zh) 2001-08-29 2005-01-26 曹卫 均相基因矩阵
EP1430112A4 (en) 2001-09-24 2005-06-15 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
CA2460959A1 (en) 2001-09-28 2003-05-22 Incyte Genomics, Inc. Enzymes
MXPA04003451A (es) 2001-10-09 2005-02-17 Dimensional Pharm Inc Difeniloxazoles substituidos, la sintesis de los mismos y el uso de los mismo como detectores fluorescencia.
WO2003033680A2 (en) 2001-10-19 2003-04-24 Incyte Genomics, Inc. Kinases and phosphatases
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
US7488598B2 (en) 2001-10-26 2009-02-10 Cornell Center For Technology Enterprise And Commercialization Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
EP1497315A2 (en) 2001-10-29 2005-01-19 Incyte Genomics, Inc. Nucleic acid-associated proteins
WO2003039523A2 (en) 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
EP1504101A2 (en) 2001-11-09 2005-02-09 Incyte Genomics, Inc. Intracellular signaling molecules
AU2002366951A1 (en) 2001-12-10 2003-07-09 Nuvelo,Inc. Novel nucleic acids and polypeptides
AU2002340387A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Cytidine libraries and compounds synthesized by solid-phase combinatorial strategies
EP1506304A2 (en) 2001-12-19 2005-02-16 Incyte Corporation Nucleic acid-associated proteins
WO2003072602A2 (en) 2001-12-20 2003-09-04 Cellzome Ag Protein complexes and methods for their use
WO2003062376A2 (en) 2002-01-16 2003-07-31 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
EP1572705A2 (en) 2002-01-17 2005-09-14 Ribapharm, Inc. Sugar modified nucleosides as viral replication inhibitors
WO2003062379A2 (en) 2002-01-17 2003-07-31 Incyte Genomics, Inc. Molecules for disease detection and treatment
WO2003062391A2 (en) 2002-01-18 2003-07-31 Incyte Corporation Structural and cytoskeleton-associated proteins
WO2003063688A2 (en) 2002-01-25 2003-08-07 Incyte Corporation Protein modification and maintenance molecules
US20050042632A1 (en) 2002-02-13 2005-02-24 Sirna Therapeutics, Inc. Antibodies having specificity for nucleic acids
US20080207542A1 (en) 2002-03-26 2008-08-28 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
AU2003216376A1 (en) 2002-02-22 2003-09-09 Incyte Corporation Enzymes
WO2003072757A2 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
JP2005524662A (ja) * 2002-02-28 2005-08-18 ビオタ インコーポレーティッド ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ
DE60323611D1 (de) 2002-03-01 2008-10-30 Integrated Dna Tech Inc Polynomiale amplifikation von nukleinsäuren
AU2003217992A1 (en) 2002-03-06 2003-09-22 Incyte Corporation Nucleic acid-associated proteins
WO2003077875A2 (en) 2002-03-15 2003-09-25 Incyte Corporation Proteins associated with growth, differentiation, and death
AU2003224811A1 (en) 2002-03-28 2003-10-13 Incyte Corporation Transporters and ion channels
WO2003083084A2 (en) 2002-03-29 2003-10-09 Incyte Corporation Protein modification and maintenance molecules
AU2003220607A1 (en) 2002-03-29 2003-10-13 Incyte Corporation Enzymes
AU2003222189A1 (en) 2002-04-05 2003-10-27 Incyte Corporation Secreted proteins
US20030190626A1 (en) 2002-04-09 2003-10-09 Vasulinga Ravikumar Phosphorothioate monoester modified oligomers
US20060074035A1 (en) * 2002-04-17 2006-04-06 Zhi Hong Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections
WO2003090674A2 (en) 2002-04-23 2003-11-06 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2003225282A1 (en) 2002-04-29 2003-11-17 Incyte Corporation Enzymes
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
WO2003094848A2 (en) 2002-05-10 2003-11-20 Incyte Corporation Nucleic acid-associated proteins
FR2840318B1 (fr) 2002-05-29 2004-12-03 Quoc Kiet Pham Nouveaux sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih
JP4902958B2 (ja) 2002-06-07 2012-03-21 ユニバーシテール・メディッシュ・セントラム・ユトレヒト ｃＡＭＰによって直接活性化される交換タンパク質（Ｅｐａｃ）の活性をモジュレートするための新規な化合物
WO2004001008A2 (en) 2002-06-21 2003-12-31 Incyte Corporation Kinases and phosphatases
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL374792A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
AU2003245747A1 (en) 2002-06-28 2004-01-19 Incyte Corporation Enzymes
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004009797A2 (en) 2002-07-23 2004-01-29 Incyte Corporation Protein modification and maintenance molecules
WO2004014312A2 (en) 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
GB0221694D0 (en) 2002-09-18 2002-10-30 Glaxo Group Ltd Compounds
CA2499036A1 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US20070207973A1 (en) 2002-09-24 2007-09-06 Koronis Pharmaceuticals, Incorporated 1,3,5-Triazines for Treatment of Viral Diseases
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003297682A1 (en) 2002-12-03 2004-06-23 Archemix Corporation Method for in vitro selection of 2'-substituted nucleic acids
US20050037394A1 (en) 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
JP5102959B2 (ja) 2002-12-23 2012-12-19 ダイナバックス テクノロジーズ コーポレイション 免疫刺激配列オリゴヌクレオチド及びその使用方法
AR043006A1 (es) 2003-02-12 2005-07-13 Merck & Co Inc Proceso para preparar ribonucleosidos ramificados
WO2004080466A1 (en) 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20090247488A1 (en) 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
UA82695C2 (uk) 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Гетероароматичні сполуки як активатори рецептора тромбопоетину
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
EP1644516A4 (en) 2003-07-14 2007-03-21 Capitalbio Corp METHOD AND COMPOSITIONS FOR DETECTING SARS VIRUS AND OTHER INFECTIOUS AGENTS
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
NZ546055A (en) 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
US7144868B2 (en) * 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
JP2007514647A (ja) 2003-10-21 2007-06-07 インスパイアー ファーマシューティカルズ，インコーポレイティド テトラヒドロ−フロ［３，４−ｄ］ジオキソール化合物並びに血小板凝集を阻害する組成物及び方法
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
CA2542776A1 (en) * 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
JP2005162732A (ja) 2003-11-13 2005-06-23 Bayer Cropscience Ag 殺虫性ニコチノイルカーバメート類
US20070238099A1 (en) 2003-12-08 2007-10-11 Cohen Irun R Antigen Receptor Variable Region Typing
WO2005077966A1 (en) 2004-02-10 2005-08-25 Isis Pharmaceuticals, Inc. Substituted pixyl protecting groups for oligonucleotide synthesis
JP2007526253A (ja) 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
US8759317B2 (en) 2004-03-18 2014-06-24 University Of South Florida Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
AU2005247509C1 (en) 2004-05-27 2012-09-20 Alnylam Pharmaceuticals, Inc. Nuclease resistant double-stranded ribonucleic acid
GB0413726D0 (en) 2004-06-18 2004-07-21 Lauras As Compounds
CA2571079A1 (en) * 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
EP1789553B1 (en) 2004-06-30 2014-03-26 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a non-phosphate backbone linkage
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006021341A1 (en) 2004-08-23 2006-03-02 F. Hoffmann-La Roche Ag Antiviral 4’-azido-nucleosides
JP2008514187A (ja) 2004-09-01 2008-05-08 ダイナバックス テクノロジーズ コーポレイション 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2006034373A2 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP2377873B1 (en) 2004-09-24 2014-08-20 Alnylam Pharmaceuticals, Inc. RNAi modulation of ApoB and uses thereof
WO2006038865A1 (en) * 2004-10-01 2006-04-13 Betagenon Ab Nucleotide derivatives for the treatment of type 2 diabetes and other disorders
CA2588979C (en) 2004-12-08 2013-01-22 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
US8003619B2 (en) 2004-12-09 2011-08-23 Alnylam Pharmaceuticals, Inc. Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
US7560544B2 (en) 2004-12-17 2009-07-14 Anadys Pharmaceuticals, Inc. 3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
CA2591582A1 (en) 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
US20070066552A1 (en) 2005-01-21 2007-03-22 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
US7638488B2 (en) 2005-03-08 2009-12-29 Intermune, Inc. Use of alpha-glucosidase inhibitors to treat alphavirus infections
CA2600886A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
JP2006248949A (ja) 2005-03-09 2006-09-21 Univ Nagoya ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法
JP2006248975A (ja) 2005-03-10 2006-09-21 Tokyo Institute Of Technology ヌクレオシドホスホロアミダイト化合物
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
ES2261072B1 (es) 2005-04-06 2007-12-16 Consejo Superior Investig. Cientificas Fosforotioatos derivados de analogos a nucleosido para terapia antirretroviral.
US20060240462A1 (en) 2005-04-21 2006-10-26 Johnson & Johnson Research Pty Limited Methods for amplification and detection of nucleic acids
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US8207136B2 (en) 2005-04-26 2012-06-26 The Board Of Trustees Of The University Of Illinois Nucleoside compounds and methods of use thereof
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
EP1893993A4 (en) 2005-06-01 2009-05-13 Scripps Research Inst CRYSTAL OF A CYTOCHROM LIGAND COMPLEX AND USE METHOD
WO2007006544A2 (en) 2005-07-12 2007-01-18 Vrije Universiteit Brussel Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders
EP2311795A3 (en) 2005-07-21 2011-12-28 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007020018A1 (en) * 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
JP5665272B2 (ja) 2005-10-07 2015-02-04 スピーデクス ピーティーワイ リミテッド 多成分核酸酵素およびそれらの使用方法
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CA2626584A1 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
JP5145563B2 (ja) 2005-11-24 2013-02-20 国立大学法人北海道大学 神経変性疾患治療薬
CA2632626C (en) 2005-12-09 2011-10-11 F. Hoffmann-La Roche Ag Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
US20090221684A1 (en) 2005-12-22 2009-09-03 Trustees Of Boston University Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof
EP1982174A4 (en) 2006-01-27 2009-05-06 Univ George Mason EYES LIQUID MARKER
EP1987050A2 (en) 2006-02-14 2008-11-05 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
EP1993611A4 (en) 2006-03-16 2013-05-22 Alnylam Pharmaceuticals Inc RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES
NZ571568A (en) 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
WO2007113159A1 (en) * 2006-04-04 2007-10-11 F. Hoffmann-La Roche Ag 3',5'-di-o-acylated nucleosides for hcv treatment
FR2900334B1 (fr) 2006-04-28 2008-06-27 Oreal Procede de depigmentation de la peau
WO2007130783A2 (en) 2006-05-03 2007-11-15 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
WO2007149554A2 (en) 2006-06-22 2007-12-27 The Johns Hopkins University Methods for restoring neural function
US8470522B2 (en) 2006-07-20 2013-06-25 Kaohsiung Medical University Three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes and preparation process and uses of the same
AU2007300663A1 (en) 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
CA2661436A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
EP2081917A2 (en) 2006-08-31 2009-07-29 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
GB0618235D0 (en) 2006-09-15 2006-10-25 Lauras As Process
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor
PL216525B1 (pl) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
AU2007333368C1 (en) 2006-11-09 2014-03-13 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US7598040B2 (en) 2006-11-22 2009-10-06 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
JP2010515680A (ja) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
CA2676822A1 (en) 2007-01-31 2008-08-07 Alios Biopharma, Inc. 2-5a analogs and their methods of use
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
CA2689042A1 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
US20120108533A1 (en) 2007-02-27 2012-05-03 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
US8242087B2 (en) 2007-02-27 2012-08-14 K.U.Leuven Research & Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
WO2008104408A2 (en) 2007-02-27 2008-09-04 K. U. Leuven Research & Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
PL211703B1 (pl) 2007-07-03 2012-06-29 Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk Tiohypofosforanowe i ditiohypofosforanowe analogi 5'-O-hypofosforanów nukleozydów i ich estry alkilowe oraz sposób ich wytwarzania
CN101108870A (zh) 2007-08-03 2008-01-23 冷一欣 核苷磷酸酯类化合物及制备方法和应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
BRPI0821106A2 (pt) 2007-11-29 2015-06-16 Ligand Pharm Inc Pró-fármacos de nucleosídeo e usos dos mesmos
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
WO2009086201A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
GB2471806B (en) 2008-04-03 2012-12-19 Spring Bank Pharmaceuticals Inc Compositions and methods for treating viral infections
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8628767B2 (en) 2008-08-15 2014-01-14 The Uab Research Foundation Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs
GB0815315D0 (en) 2008-08-21 2008-09-24 Univ Leiden Organ protection
US8163707B2 (en) * 2008-09-15 2012-04-24 Enanta Pharmaceuticals, Inc. 4′-allene-substituted nucleoside derivatives
EP2166016A1 (en) * 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
US20120059045A1 (en) 2008-10-24 2012-03-08 Isis Pharmaceuticals, Inc. Methods of using oligomeric compounds comprising 2'-substituted nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US8759318B2 (en) * 2009-01-09 2014-06-24 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
EP2393815A4 (en) 2009-02-06 2012-11-21 Rfs Pharma Llc PURIN NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF CANCER AND VIRUS INFECTIONS
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
US20100297079A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
WO2011005595A2 (en) 2009-06-24 2011-01-13 Alios Biopharma, Inc. 2-5a analogs and their methods of use
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
RU2012136824A (ru) 2010-01-29 2014-03-10 Вертекс Фармасьютикалз Инкорпорейтед Способы лечения вирусной инфекции гепатита с
WO2011156757A1 (en) 2010-06-10 2011-12-15 Gilead Sciences, Inc. Combination of anti-hcv compounds with ribavirin for the treatment of hcv
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
NZ607996A (en) * 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
CA2819041A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
GEP201706721B (en) 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CA2908313A1 (en) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Hepatitis c viral infection treatment using a combination of compounds
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230028486A (ko) * 2020-06-24 2023-02-28 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오시드 유사체 및 이의 용도

Also Published As

Publication number Publication date
JP6012605B2 (ja) 2016-10-25
CO6690792A2 (es) 2013-06-17
AP2013006824A0 (en) 2013-04-30
JP6163193B2 (ja) 2017-07-12
WO2012040127A1 (en) 2012-03-29
EA201390230A1 (ru) 2013-09-30
AR083070A1 (es) 2013-01-30
PH12015501953A1 (en) 2017-04-10
PH12013500629A1 (en) 2019-10-11
CN105061534A (zh) 2015-11-18
HK1216254A1 (zh) 2016-10-28
CN103209987B (zh) 2017-06-06
CN103209987A (zh) 2013-07-17
EP2619216A1 (en) 2013-07-31
UY33621A (es) 2012-04-30
ECSP13012572A (es) 2015-02-28
SG188497A1 (en) 2013-05-31
JP2013537907A (ja) 2013-10-07
EP2619216A4 (en) 2014-04-02
CL2013000755A1 (es) 2013-10-04
CA2810928A1 (en) 2012-03-29
PE20171640A1 (es) 2017-11-09
US8871737B2 (en) 2014-10-28
TW201217392A (en) 2012-05-01
US9278990B2 (en) 2016-03-08
BR112013005872A2 (pt) 2019-09-24
AU2011305655A1 (en) 2013-05-02
EA025341B1 (ru) 2016-12-30
NZ607996A (en) 2014-07-25
US20150038451A1 (en) 2015-02-05
JP2016065080A (ja) 2016-04-28
MX2013003153A (es) 2013-05-01
AP3584A (en) 2016-02-09
GEP20156313B (en) 2015-07-10
PE20140608A1 (es) 2014-06-12
AU2011305655B2 (en) 2015-11-05
US20120071434A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
US12173025B2 (en) Substituted nucleosides, nucleotides and analogs thereof
US9278990B2 (en) Substituted nucleotide analogs
US9605018B2 (en) Substituted nucleotide analogs
EP2655392B1 (en) Cyclic nucleotide analogs
AU2013361193B2 (en) Substituted nucleosides, nucleotides and analogs thereof
US20120070411A1 (en) Substituted nucleotide analogs
HK40064928A (en) 4’-fluoro-nucleosides, 4’-fluoro-nucleotides and analogs thereof for the treatment of hcv
HK1187350A (zh) 取代的核苷酸類似物
OA16349A (en) Substituted nucleotide analogs
HK1216536B (en) 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130419

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160913

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180704

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180907

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180704

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I